vs
Side-by-side financial comparison of Applied Therapeutics, Inc. (APLT) and Coeptis Therapeutics Holdings, Inc. (COEP). Click either name above to swap in a different company.
Applied Therapeutics, Inc. is the larger business by last-quarter revenue ($1.0M vs $862.0K, roughly 1.2× Coeptis Therapeutics Holdings, Inc.). Coeptis Therapeutics Holdings, Inc. runs the higher net margin — -146.5% vs -1899.0%, a 1752.5% gap on every dollar of revenue.
Relief Therapeutics is a Swiss biopharmaceutical company based in Geneva. The company focuses on developing drugs for serious diseases with few or no existing treatment options. Its lead compound, RLF-100, is a synthetic form of a natural peptide that protects the lung. The company was incorporated as Relief Therapeutics Holdings AG (RFLB.S) and listed on the SIX Swiss Exchange in 2016.
Coeptis Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative cancer immunotherapies, including cell therapy and antibody-based treatment candidates, to address unmet medical needs for patients with hard-to-treat malignancies. It primarily operates in the U.S., advancing its product pipeline across multiple oncology segments.
APLT vs COEP — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $1.0M | $862.0K |
| Net Profit | $-19.0M | $-1.3M |
| Gross Margin | — | 94.8% |
| Operating Margin | -1675.8% | -230.6% |
| Net Margin | -1899.0% | -146.5% |
| Revenue YoY | 719.7% | — |
| Net Profit YoY | 72.3% | 55.1% |
| EPS (diluted) | $-0.13 | $0.05 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $862.0K | ||
| Q3 25 | $1.0M | $237.4K | ||
| Q2 25 | $0 | $200.7K | ||
| Q1 25 | $0 | $62.9K | ||
| Q4 24 | $-1.0K | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | $144.0K | $0 | ||
| Q1 24 | $190.0K | $0 |
| Q4 25 | — | $-1.3M | ||
| Q3 25 | $-19.0M | $-2.9M | ||
| Q2 25 | $-21.3M | $-4.3M | ||
| Q1 25 | $-21.8M | $-3.4M | ||
| Q4 24 | $44.0M | $-2.8M | ||
| Q3 24 | — | $-1.8M | ||
| Q2 24 | $2.9M | $-3.0M | ||
| Q1 24 | $-83.9M | $-3.0M |
| Q4 25 | — | 94.8% | ||
| Q3 25 | — | 81.0% | ||
| Q2 25 | — | 77.5% | ||
| Q1 25 | — | 28.2% | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | -230.6% | ||
| Q3 25 | -1675.8% | -1043.2% | ||
| Q2 25 | — | -2252.9% | ||
| Q1 25 | — | -6452.6% | ||
| Q4 24 | 3302300.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -14194.4% | — | ||
| Q1 24 | -11101.6% | — |
| Q4 25 | — | -146.5% | ||
| Q3 25 | -1899.0% | -1220.8% | ||
| Q2 25 | — | -2159.9% | ||
| Q1 25 | — | -5440.9% | ||
| Q4 24 | -4400700.0% | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 2012.5% | — | ||
| Q1 24 | -44177.9% | — |
| Q4 25 | — | $0.05 | ||
| Q3 25 | $-0.13 | $-0.58 | ||
| Q2 25 | $-0.15 | $-1.17 | ||
| Q1 25 | $-0.15 | $-1.11 | ||
| Q4 24 | $0.52 | $-5.35 | ||
| Q3 24 | — | $-0.05 | ||
| Q2 24 | $-0.13 | $-0.08 | ||
| Q1 24 | $-0.67 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $11.9M | $676.6K |
| Total DebtLower is stronger | — | $150.0K |
| Stockholders' EquityBook value | $-561.0K | $13.6M |
| Total Assets | $34.4M | $16.2M |
| Debt / EquityLower = less leverage | — | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $676.6K | ||
| Q3 25 | $11.9M | $421.7K | ||
| Q2 25 | $30.4M | $990.6K | ||
| Q1 25 | $50.8M | — | ||
| Q4 24 | $79.4M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $122.2M | — | ||
| Q1 24 | $146.5M | — |
| Q4 25 | — | $150.0K | ||
| Q3 25 | — | $150.0K | ||
| Q2 25 | — | $150.0K | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $150.0K | ||
| Q3 24 | — | $1.7M | ||
| Q2 24 | — | $1.7M | ||
| Q1 24 | — | $2.3M |
| Q4 25 | — | $13.6M | ||
| Q3 25 | $-561.0K | $10.4M | ||
| Q2 25 | $17.4M | $6.1M | ||
| Q1 25 | $36.7M | $6.5M | ||
| Q4 24 | $57.0M | $3.4M | ||
| Q3 24 | — | $4.8M | ||
| Q2 24 | $72.4M | $-442.6K | ||
| Q1 24 | $67.3M | $-1.1M |
| Q4 25 | — | $16.2M | ||
| Q3 25 | $34.4M | $14.2M | ||
| Q2 25 | $37.3M | $12.2M | ||
| Q1 25 | $56.9M | $13.5M | ||
| Q4 24 | $86.7M | $8.9M | ||
| Q3 24 | — | $9.0M | ||
| Q2 24 | $127.8M | $4.2M | ||
| Q1 24 | $151.2M | $3.9M |
| Q4 25 | — | 0.01× | ||
| Q3 25 | — | 0.01× | ||
| Q2 25 | — | 0.02× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.04× | ||
| Q3 24 | — | 0.35× | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.4M | $-8.6M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-8.6M | ||
| Q3 25 | $-18.4M | $-2.2M | ||
| Q2 25 | $-20.3M | $-2.4M | ||
| Q1 25 | $-28.6M | $-2.4M | ||
| Q4 24 | $-19.5M | $-6.6M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | $-22.6M | $-1.4M | ||
| Q1 24 | $-18.9M | $-1.9M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | -0.44× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | -7.80× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
